
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A precision oncology guide on liquid biopsy ctDNA next-generation sequencing in non-small cell lung cancer, evaluating EGFR/ALK drivers, Osimertinib resistance mechanisms (C797S, MET), and minimal residual disease tracking.
CRITICAL CLINICAL RED FLAG: In patients on targeted TKIs for metastatic EGFR/ALK NSCLC, asymptomatic molecular disease progression can precede radiographic RECIST enlargement by 2 to 6 months; serial ctDNA liquid biopsy enables early intervention before symptomatic clinical deterioration.
While tissue biopsy remains the gold standard for initial histological diagnosis of Non-Small Cell Lung Cancer (NSCLC), up to 30% of patients have insufficient or inaccessible tissue for comprehensive biomarker testing. Liquid biopsy via cell-free circulating tumor DNA (ctDNA) overcomes spatial tumor heterogeneity and provides rapid, non-invasive genomic profiling with turnaround times under 7 to 10 days.
First-Line Driver Mapping: Detects classic EGFR (Exon 19 del, L858R), ALK/ROS1 fusions, RET fusions, MET Exon 14 skipping, BRAF V600E, and KRAS G12C mutations.
Resistance Mechanism Tracking: Identifies secondary resistance mutations following Osimertinib failure, including EGFR C797S, MET amplification, and small cell histological transformation.
Minimal Residual Disease (MRD): Post-surgical ctDNA clearance predicts curative resection vs. high risk of distant metastatic relapse in early-stage NSCLC.
In resected Stage IB-IIIA EGFR-mutated NSCLC, patients who remain ctDNA-positive following surgical resection and adjuvant Osimertinib demonstrate imminent micrometastatic recurrence. Serial plasma monitoring enables personalized treatment intensification or switch therapies months before lesions appear on PET-CT scans.
"Liquid biopsy is not just a diagnostic tool; it is a real-time molecular window into tumor clonal evolution, allowing us to anticipate and neutralize drug resistance before cancer spreads." — Dr. Neha Gupta
According to ASCO and IASLC guidelines:
Positive ctDNA result: Actionable and sufficient to immediately initiate targeted TKI therapy without requiring repeat invasive tissue biopsy.
Negative ctDNA result: Requires tissue biopsy confirmation (reflex testing) due to potential false negatives in low-shedding or intracranial-only lesions.
1. Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer (IASLC). Journal of Thoracic Oncology (JTO), 2021; 16(10): 1647-1662.
2. Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC (ADAURA Trial). New England Journal of Medicine (NEJM), 2023; 389: 137-147.
3. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Tyrosine Kinase Inhibitors: Guideline from CAP, IASLC, and AMP. Arch Pathol Lab Med, 2018; 142(3): 321-346.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.